Europeans are facing decreased access to new medicines and the ability to take part in ground-breaking clinical trials, as research and development of new treatments increasingly moves to more ambitious life science sectors in the US and Asia.
A new report published today by Charles River Associates for EFPIA paints a challenging picture of falling competitiveness in Europe, with the global share of pharmaceutical R&D investment, clinical trials and manufacturing output all decreasing.
Unlocking the potential of precision medicine in Europe – improving cancer care through broader access to quality biomarker...
Read more
Opening remarks by Nathalie Moll at the POLITICO Health Care Summit
As Europe emerges from the COVID-19 pandemic and faces a geopolitical and energy crisis, ensuring Europe remains an innovation centre is crucial to Europe’s patients and economic resilience. Our request is that while legislators focus the revision of the pharma legislation on the regulatory review to make our region competitive again, we all commit now, to working together to find predictable, practical and timely solutions to improving access to medicines, outside of the review of legislation.
Join the webinar to get information on how to apply and to meet potential partners for consortia.
Read more
Interested in the use and acceptance of digital endpoints?
WE NEED YOUR HELP to complete a survey meant to further assess the current status of digital endpoints used in drug development and to collect experience in the current environment and feedback on what the barriers and potential solutions are: Deadline for survey completion: 15 November 2022.
While Ireland’s industry is healthy, the outlook is uncertain, and now is the time to establish new connections
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.